1. Generics Bulletin
  2. >>Business

Kabi Awaits Biosimilar Tocilizumab Boost, Upgrades 2024 Guidance

Follows Recent US Launch And Increasing European Roll Out, ‘Very Confident’

 
• By Dean Rudge

Fresenius Kabi enjoyed a good start to 2024, boosted by the recent US launch of its biosimilar tocilizumab product and a key licensing agreement signed with Teva – factors that have allowed the German generics and biosimilars giant to boost its financial guidance for 2024.

Andrii Yalanskyi/Alamy Stock Photo
• Source: Shutterstock (Andrii Yalanskyi / Alamy Stock P/Alamy Stock Photo)

Fresenius Kabi believes “everything is working according to plan” following its recent launch of the first US biosimilar Actemra (tocilizumab), its Tyenne (tocilizumab-aazg) intravenous formulation, and says it has been “working very hard on access,” although the German firm concedes that the financial benefits will be muted for a couple of quarters.

“Everything looks very promising

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.